摘要
采用重组干扰素α联合拉米夫定治疗慢性乙型肝炎（下简称慢乙肝）患者３１例（Ａ组），并与３１例仅行保肝和对症治疗的慢乙肝患者（Ｂ组）进行疗效比较。结果显示，两组临床、生化指标均获改善；Ａ组ＨＢｅＡｇ阴转率为６５．５％，Ｂ组仅１０．７％，两组比较差异显著（Ｐ＜０．０１）；Ａ组ＨＢＶ－ＤＮＡ均转阴，而Ｂ组无１例阴转。认为干扰素α联合拉米夫定治疗慢乙肝可改善患者的肝功、稳定病情，提高ｅ抗原阴转率。
The curative effect of interferon alpha plus lamivudine for
31 cases of chronic hapatitis B (group A)and hepatoprotective therapy for 31 cases of chronic
hapatitis B(group B)was compared.The result showed that the improved degree in clinical and
biochemical parameters of two groups were similar.The negative rate of HBeAg of group A and
B were 65.5%,10.7% respectively,the difference of two rates were obvious.The serum HBVDNA
were all negative in group A,but none in groupB.This suggest that interferon alpha plus
lamivudine can improve the liver function,stabilize patients condition,rasie negative rate of
HBeAg of patients with chronic hepatitis B
出处
《山东医药》
CAS
北大核心
1999年第11期3-4,共2页
Shandong Medical Journal
